S&P 500 rises as health care, tech gain to overshadow Fed independence concerns
On June 9, 2025, Joshua R. Disbrow, the Chief Executive Officer of Aytu BioPharma, Inc. (NASDAQ:AYTU), purchased a significant amount of the company’s common stock. According to a recent SEC filing, Disbrow acquired 66,666 shares at a price of $1.50 per share, totaling $99,999. The stock has since rallied to $2.10, delivering a remarkable 36% return in the past week. InvestingPro analysis indicates the company is currently trading at an attractive revenue multiple. This transaction was conducted as part of Aytu BioPharma’s registered offering, as outlined in the company’s Registration Statement on Form S-1 filed earlier this month. Following this acquisition, Disbrow’s direct ownership in Aytu BioPharma increased to 153,257 shares. While the company wasn’t profitable in the last twelve months, InvestingPro data shows analysts expect profitability this year. Discover more insights about AYTU and track insider trading patterns with InvestingPro’s comprehensive research reports, available for 1,400+ US stocks.
In other recent news, Aytu BioPharma reported a strong financial performance in the third quarter of fiscal year 2025. The company achieved a 32% increase in net revenue year-over-year, reaching $18.5 million, which was driven by significant growth in its ADHD and pediatric portfolios. Aytu BioPharma also reported a net income of $4 million, marking a turnaround from a loss in the prior year, and achieved an adjusted EBITDA of $3.9 million. The company’s ADHD portfolio generated $15.4 million in revenue, up 25% from the previous year, while the pediatric portfolio saw a 77% increase, contributing $3.1 million to the total revenue. Additionally, Aytu BioPharma has secured exclusive rights to commercialize EXXUA™, a new FDA-approved antidepressant for major depressive disorder, in the U.S. market. The company plans to launch EXXUA in the fourth quarter of 2025, with strong financial backing from Nantahala Capital Management and other institutional investors. The financial terms of the agreement with Fabre-Kramer Pharmaceuticals include upfront payments, royalties, and performance-based milestone payments. Aytu BioPharma is also exploring strategic acquisitions to complement its existing product lines, particularly in the CNS and pediatric therapeutic areas.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.